SGLT2 Inhibitors May Delay Kidney Disease

Drugs from the SGLT2 inhibitor class of diabetes medications have shown benefit in slowing progression of diabetic kidney disease, with a reduced risk of acute kidney injury (AKI) noted in research trials. People at high risk of AKIs who may be considering SGLT2 treatment should discuss the risks and benefits with their doctors. Read more

Posted in Type II Drugs